PhaseBio Pharmaceuticals has started a Phase IIa clinical trial of PE0139, a potential treatment for hyperglycemia associated with diabetes.

PE0139 is a fusion of a fully mature, native insulin molecule with the company’s polypeptide biopolymer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PhaseBio develops treatments for metabolic and cardiopulmonary disorders.

“PE0139 was well tolerated in a Phase I study, and demonstrated a flat PK profile.”

The trial will evaluate the safety and tolerability of PE0139, as well as the pharmacokinetic (PK) and pharmacodynamic response in adult patients.

Patients tested will have type 2 diabetes mellitus. Up to 50 patients will be given a once-weekly subcutaneous injection of PE0139 for six weeks.

The trial will be multicentre, randomised, and placebo controlled.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PhaseBio chief executive officer Jonathan Mow said: “This Phase IIa study represents a key milestone for PhaseBio as we advance the development of PE0139, which has the potential to be the first once-weekly insulin to market.

“PE0139 was well tolerated in a Phase I study, and demonstrated a flat PK profile essential for once-weekly dosing.

“We look forward to continuing to evaluate PE0139 with the goal of providing better treatment options for people with diabetes.”

In non-clinical models of diabetes, PE0139 caused a longer reduction in blood glucose compared to insulin glargine.

In further non-clinical trials, PE0139 showed a strong synergistic action with PB1023, PhaseBio’s weekly GLP-1 receptor agonist.